Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

@article{Sureda2005PrognosticFA,
  title={Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.},
  author={Anna Sureda and M. Gr{\`a}cia Coll Constans and Alexander Iriondo and R M Provencio Arranz and Mª Dolores Caballero and Maria J. Vidal and Joel A Petit and Antonio Aznar L{\'o}pez and Juan Jos{\'e} Mart{\'i}nez Lahuerta and Elena Orozco Carreras and Javier Garcia-conde and Jos{\'e} Garc{\'i}a-Lara{\~n}a and Roberto C V{\'a}squez Cabrera and Isidro Jarque and Dolores Carrera and Juan Carlos Garc{\'i}a-Ru{\'i}z and Maria Jesus Espinosa Pascual and J. Rif{\'o}n and Jose M Moraleda and Katty P{\'e}rez-Equiza and C Xavier Alb{\'o} and Joaqu{\'i}n D{\'i}az-Mediavilla and Ana L Teller{\'i}a Torres and Patricia Prat Torres and Juan Besalduch and Jes{\'u}s Rodr{\'i}guez Mar{\'i}n and Maria Vitoria Mateos and Jos{\'e} Mar{\'i}a Fern{\'a}ndez-Ra{\~n}ada and Jorge Sierra and Eduardo G{\'o}mez Conde},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 4},
  pages={
          625-33
        }
}
PURPOSE To analyse outcome and prognostic factors for overall survival (OS) and time to treatment failure (TTF) in 357 patients with Hodgkin's lymphoma (HL) undergoing an autologous stem cell transplantation (ASCT) after a first relapse and reported to the The Grupo Espanol de Linfomas/Trasplante Autologo de Medula Osea (GEL/TAMO) Cooperative Group. METHODS Two hundred and twenty males and 137 females with a median age of 29 years were autografted in second remission (n=181), first sensitive… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 68 CITATIONS, ESTIMATED 45% COVERAGE

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Informe de Posicionamiento Terapéutico de nivolumab (Opdivo®) en el tratamiento de Linfoma de Hodgkin

Informe de Posicionamiento, Linfoma de Hodgkin, NIVOLUMAB OPDIVO
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2018

FILTER CITATIONS BY YEAR

2006
2018

CITATION STATISTICS

  • 4 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Autologous hematopoietic cell transplantation (ASCT) for patients with chemo-refractory Hodgkin’s lymphoma (HL)

HC Fung, A Nademanee, A Krishnan
  • Blood
  • 2003
VIEW 1 EXCERPT

Risk-adapted high dose chemoradiotherapy and ASCT for patients with relapsed or refractory Hodgkin’s disease: An intent to treat analysis

CH Moskowitz, T Kewalramani, SD Nimer
  • Blood
  • 2003
VIEW 1 EXCERPT

Autologous stem cell transplantation in Hodgkin's disease.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2002